Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 10 de 10
Filter
Add more filters










Publication year range
4.
Am J Clin Dermatol ; 19(3): 319-332, 2018 Jun.
Article in English | MEDLINE | ID: mdl-29285724

ABSTRACT

Atopic dermatitis (AD) is the most common itchy dermatosis that affects millions of children and adults worldwide. Chronic itch in this condition has significant impact on measures of quality of life, such as sleep. Treating itch in AD has been challenging for decades, but new drugs have emerged in the last year with significant anti-pruritic effect. The optimal treatment regimen for atopic itch addresses barrier dysfunction, inflammation, neural hypersensitivity, and the itch-scratch cycle. Topical moisturizers remain the foundation of treatment and should be used by all patients with AD-associated pruritus. Step-wise therapy, from topical anti-inflammatory creams to systemic monoclonal antibodies and immunosuppressants, is recommended. There are multiple adjuvant therapies that can be used, especially to target itch in the setting of minimal skin inflammation. Finally, patient education, sleep management, and stress relief are important components to optimize outcomes. This review assesses the latest advances and treatment recommendations for pruritus in AD. Finally, suggested therapeutic ladders and emerging treatments are discussed.


Subject(s)
Dermatitis, Atopic/therapy , Dermatologic Agents/therapeutic use , Hypersensitivity/drug therapy , Nervous System/drug effects , Pruritus/therapy , Administration, Cutaneous , Administration, Oral , Analgesics/pharmacology , Analgesics/therapeutic use , Bandages , Dermatitis, Atopic/complications , Dermatitis, Atopic/pathology , Dermatologic Agents/pharmacology , Filaggrin Proteins , Humans , Hypersensitivity/immunology , Intermediate Filament Proteins/genetics , Intermediate Filament Proteins/metabolism , Nervous System/immunology , Patient Education as Topic , Phototherapy/methods , Pruritus/etiology , Pruritus/immunology , Pruritus/pathology , Quality of Life , Skin/drug effects , Skin/immunology , Skin/innervation , Skin/pathology , Skin Cream/therapeutic use
5.
J Cutan Pathol ; 44(7): 639-642, 2017 Jul.
Article in English | MEDLINE | ID: mdl-28419495

ABSTRACT

Nevus sebaceus of Jadassohn, a congenital cutaneous hamartoma, has the potential to develop into various epidermal adnexal-origin neoplasms. While the most common neoplasms are trichoblastoma or syringocystadenoma, proliferating trichilemmal cysts are exceptionally rare. We report a case of a 63-year-old Cuban male with a giant proliferating trichilemmal cyst arising from a nevus sebaceus on the right shoulder which had been growing for 30 years. Proliferating trichilemmal cysts arising from nevus sebaceus cases are difficult to diagnose clinically and histologically as they are very rare and have not been defined by exact diagnostic criteria. Our case creates awareness of this particular tumor in nevus sebaceus and shares clinical and histological diagnostic information that can be used to make a proper diagnosis.

7.
J Invest Dermatol ; 137(5): e53, 2017 May.
Article in English | MEDLINE | ID: mdl-30477722
8.
J Drugs Dermatol ; 15(7): 891-2, 2016 Jul 01.
Article in English | MEDLINE | ID: mdl-27391641

ABSTRACT

Xanthelasma palpebrae are common lesions on both medical and dermatology patients. They are significant from both medical and dermatologic perspectives. They serve as a sentinel for elevated cholesterol as well as a cosmetic dermatologic issue. Treatment of these lesions requires consideration of diagnosing and treating any underlying cholesterol problem as well as removal of existing lesions. We report a simple yet effective method for treatment of these lesions.

J Drugs Dermatol. 2016;15(7):891-892.


Subject(s)
Electrosurgery/methods , Eyelid Diseases/diagnosis , Eyelid Diseases/surgery , Xanthomatosis/diagnosis , Xanthomatosis/surgery , Female , Humans , Middle Aged , Treatment Outcome
9.
PLoS One ; 8(1): e54339, 2013.
Article in English | MEDLINE | ID: mdl-23365660

ABSTRACT

BACKGROUND: Mitochondrial dysfunction is associated with the development and progression of age-related macular degeneration (AMD). Recent studies using populations from the United States and Australia have demonstrated that AMD is associated with mitochondrial (mt) DNA haplogroups (as defined by combinations of mtDNA polymorphisms) that represent Northern European Caucasians. The aim of this study was to use the cytoplasmic hybrid (cybrid) model to investigate the molecular and biological functional consequences that occur when comparing the mtDNA H haplogroup (protective for AMD) versus J haplogroup (high risk for AMD). METHODOLOGY/PRINCIPAL FINDINGS: Cybrids were created by introducing mitochondria from individuals with either H or J haplogroups into a human retinal epithelial cell line (ARPE-19) that was devoid of mitochondrial DNA (Rho0). In cybrid lines, all of the cells carry the same nuclear genes but vary in mtDNA content. The J cybrids had significantly lower levels of ATP and reactive oxygen/nitrogen species production, but increased lactate levels and rates of growth. Q-PCR analyses showed J cybrids had decreased expressions for CFH, C3, and EFEMP1 genes, high risk genes for AMD, and higher expression for MYO7A, a gene associated with retinal degeneration in Usher type IB syndrome. The H and J cybrids also have comparatively altered expression of nuclear genes involved in pathways for cell signaling, inflammation, and metabolism. CONCLUSION/SIGNIFICANCE: Our findings demonstrate that mtDNA haplogroup variants mediate not only energy production and cell growth, but also cell signaling for major molecular pathways. These data support the hypothesis that mtDNA variants play important roles in numerous cellular functions and disease processes, including AMD.


Subject(s)
DNA, Mitochondrial/genetics , Epithelial Cells/metabolism , Gene Expression , Hybrid Cells/metabolism , Macular Degeneration/genetics , Mitochondria/genetics , Signal Transduction/genetics , Adenosine Triphosphate/biosynthesis , Cells, Cultured , Complement C3/genetics , Complement C3/metabolism , Complement Factor H/genetics , Complement Factor H/metabolism , DNA, Mitochondrial/metabolism , Epithelial Cells/cytology , Extracellular Matrix Proteins/genetics , Extracellular Matrix Proteins/metabolism , Haplotypes , Humans , Hybrid Cells/pathology , Lactic Acid/metabolism , Macular Degeneration/metabolism , Macular Degeneration/pathology , Mitochondria/metabolism , Models, Biological , Myosin VIIa , Myosins/genetics , Myosins/metabolism , Reactive Nitrogen Species/metabolism , Reactive Oxygen Species/metabolism , Retinal Pigment Epithelium/cytology , Retinal Pigment Epithelium/metabolism
10.
Lasers Surg Med ; 44(3): 205-10, 2012 Mar.
Article in English | MEDLINE | ID: mdl-22302773

ABSTRACT

BACKGROUND AND OBJECTIVE: Tissue effects of vascular lesion laser treatment are incompletely understood. Injury caused by pulsed dye laser (PDL) treatment may result in altered expression of mediators associated with angiogenesis. MATERIALS AND METHODS: Eight human subjects had one angioma treated with PDL (7 mm, 1.5 millisecond pulse duration, 9 J/cm(2), cryogen spray cooling of 30 millisecond with a 30 millisecond delay). One week later, three biopsies were taken: normal skin, untreated angioma, angioma post-PDL. Tissue was frozen and sections processed for immunohistochemistry staining of vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), matrix metalloproteinase 9 (MMP-9), and angiopoietin 2 (ANG-2). Images were graded in a blinded fashion by a board certified dermatopathologist. RESULTS: There were no clear trends in VEGF expression in the epidermis, dermis, or endothelial cells. As compared to normal skin, angiomas demonstrated the following: bFGF was decreased in the epidermis; MMP-9 was decreased or unchanged in the epidermis and increased in the endothelial cells; ANG-2 was increased in the endothelial cells. When comparing normal skin to angiomas + PDL, bFGF was decreased in the epidermis and increased in the dermis; MMP-9 was decreased or unchanged in the epidermis; ANG-2 was again increased in the endothelial cells. Comparison of staining in angioma to angioma + PDL samples revealed increased dermal bFGF expression. CONCLUSION: Alterations in angiogenesis mediators were noted after PDL. Angiogenesis mediator changes associated with PDL treatment differed from those previously reported for incisional biopsies. This pilot study can guide future work on laser-induced alterations in vascular lesions and such information may ultimately be used to optimize treatment outcomes.


Subject(s)
Angiogenic Proteins/analysis , Biomarkers, Tumor/analysis , Hemangioma/chemistry , Hemangioma/surgery , Skin Neoplasms/chemistry , Skin Neoplasms/surgery , Angiopoietin-2/analysis , Fibroblast Growth Factor 2/analysis , Hemangioma/pathology , Humans , Immunohistochemistry , Lasers, Dye , Matrix Metalloproteinase 9/analysis , Pilot Projects , Skin Neoplasms/pathology , Vascular Endothelial Growth Factor A/analysis
SELECTION OF CITATIONS
SEARCH DETAIL
...